![Stewart M. Kroll](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stewart M. Kroll
Plus aucun poste en cours
Historique de carrière de Stewart M. Kroll
Anciens postes connus de Stewart M. Kroll
Sociétés | Poste | Début | Fin |
---|---|---|---|
LA JOLLA PHARMACEUTICAL COMPANY | Corporate Officer/Principal | 01/01/2020 | 01/09/2022 |
ODONATE, INC. | Corporate Officer/Principal | 01/01/2017 | 01/10/2021 |
Biometrics, Inc. | Corporate Officer/Principal | 01/01/2017 | 01/01/2019 |
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Directeur des opérations | 11/03/2016 | 30/09/2016 |
Directeur Technique/Scientifique/R&D | 01/03/2007 | 01/05/2011 | |
Corporate Officer/Principal | 01/01/2005 | 11/03/2016 | |
Corixa Corp.
![]() Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Corporate Officer/Principal | 01/12/2000 | 01/01/2005 |
Coulter Pharmaceuticals, Inc.
![]() Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Corporate Officer/Principal | 01/01/1997 | 01/12/2000 |
Formation de Stewart M. Kroll
University of California, Berkeley | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
2 |
Opérationnelle
Corporate Officer/Principal | 6 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 2 |
Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ODONATE, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Corixa Corp.
![]() Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Coulter Pharmaceuticals, Inc.
![]() Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
La Jolla Pharmaceutical Co.
![]() La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Biometrics, Inc. | Technology Services |
- Bourse
- Insiders
- Stewart M. Kroll
- Expérience